NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CORT

Corcept Therapeutics Inc

May 08 • 04:00PM ET

71.38

Dollar change +0.92
Percentage change 1.31	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: IJR VTI VB VXF VBK IWM IJT SPSM IWO VTWO

Scroll to Statements

Index	RUT	P/E	61.96	EPS (ttm)	1.15	Insider Own	11.64%	Shs Outstand	105.98M	Perf Week	-0.14%
Market Cap	7.57B	Forward P/E	26.83	EPS next Y	2.66	Insider Trans	-4.35%	Shs Float	93.70M	Perf Month	1.26%
Income	132.49M	PEG	0.89	EPS next Q	0.19	Inst Own	78.68%	Short Float	13.11%	Perf Quarter	4.91%
Sales	685.45M	P/S	11.04	EPS this Y	12.05%	Inst Trans	-7.12%	Short Ratio	7.48	Perf Half Y	42.59%
Book/sh	6.45	P/B	11.07	EPS next Y	93.00%	ROA	17.64%	Short Interest	12.29M	Perf Year	197.79%
Cash/sh	3.04	P/C	23.45	EPS next 5Y	69.46%	ROE	21.52%	52W Range	23.90 - 117.33	Perf YTD	41.66%
Dividend Est.	-	P/FCF	42.73	EPS past 5Y	9.89%	ROI	19.23%	52W High	-39.16%	Beta	0.18
Dividend TTM	-	Quick Ratio	2.96	Sales past 5Y	17.73%	Gross Margin	98.43%	52W Low	198.66%	ATR (14)	4.97
Dividend Ex-Date	-	Current Ratio	3.07	EPS Y/Y TTM	11.78%	Oper. Margin	16.17%	RSI (14)	52.32	Volatility	5.83% 6.39%
Employees	500	Debt/Eq	0.01	Sales Y/Y TTM	30.93%	Profit Margin	19.33%	Recom	1.00	Target Price	138.25
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-32.36%	Payout	0.00%	Rel Volume	0.74	Prev Close	70.46
Sales Surprise	-11.64%	EPS Surprise	19.30%	Sales Q/Q	7.09%	Earnings	May 05 AMC	Avg Volume	1.64M	Price	71.38
SMA20	2.90%	SMA50	8.07%	SMA200	32.97%	Trades		Volume	1,220,832	Change	1.31%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$14
Apr-21-15	Initiated	FBR Capital	Outperform	$12
Jan-13-14	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

May-08-25 12:34AM	1 Small-Cap Stock Worth Your Attention and 2 to Question (StockStory)
May-07-25 10:01AM	Corcept Therapeutics price target lowered to $135 from $150 at Truist (TipRanks)
May-06-25 02:50PM	Q1 2025 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks)
03:08AM	Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ... (GuruFocus.com)
08:34PM	Loading…
May-05-25 08:34PM	Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks)
04:26PM	Corcept: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (Business Wire)
May-04-25 05:25PM	Corcept Therapeutics (CORT): Among Billionaire Jim Simons' RenTech's Small-Cap Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-30-25 08:11PM	Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? (Insider Monkey)
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
06:20AM	Should iShares Core S&P Small-Cap ETF (IJR) Be on Your Investing Radar? (Zacks)
06:20AM	Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar? (Zacks)
04:05PM	Loading…
Apr-28-25 04:05PM	CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL (Business Wire)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-23-25 06:06PM	BBSC: Lagging Several Small-Cap Core ETFs (Seeking Alpha) +7.10%
12:55PM	Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
11:30AM	CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 (Business Wire)
Apr-22-25 05:23PM	Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss (Seeking Alpha)
Apr-21-25 08:00AM	Diabetes Care Publishes Results From Prevalence Phase Of Corcepts CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes (Business Wire)
06:20AM	Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now? (Zacks)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 06:20AM	Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar? (Zacks)
Apr-15-25 04:00PM	It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder (Seeking Alpha) -7.17%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -7.18%
Apr-07-25 08:00AM	Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer (Business Wire)
Apr-04-25 09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks) -6.20%
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -5.30%
09:08AM	Loading…
09:08AM	NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program (Zacks)
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks) -8.83%
09:55AM	Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? (Zacks)
09:11AM	APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
Apr-01-25 01:43PM	Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release (Seeking Alpha) -19.51%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks)
10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks)
09:31AM	AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication (Zacks)
08:50AM	Here's Why Momentum in Corcept (CORT) Should Keep going (Zacks)
07:15AM	Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company (Seeking Alpha)
07:13AM	Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? (Insider Monkey)
05:39AM	Corcepts Phase III trial of ovarian cancer therapy shows PFS improvement (Clinical Trials Arena)
Mar-31-25 02:48PM	Why Is Corcept (CORT) Stock Soaring Today (StockStory) +109.08%
01:20PM	NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute (Yahoo Finance Video)
11:51AM	Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers (Yahoo Finance Video)
08:18AM	Corcept's ovarian cancer drug cuts disease progression in study, shares jump (Reuters)
08:00AM	Primary Endpoint Met in Corcepts Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Mar-28-25 11:30AM	Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? (Zacks)
09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 12:03PM	ClearBridge Small Cap Fund Q4 2024 Commentary (SeekingAlpha)
09:39AM	PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know (Zacks)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:41PM	3 Reasons to Sell CORT and 1 Stock to Buy Instead (StockStory)
Mar-21-25 09:40AM	Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-19-25 09:03AM	3 Growth Stocks in Hot Water (StockStory)
Mar-14-25 09:03AM	1 Small-Cap Stock on Our Buy List and 2 to Avoid (StockStory)
Mar-10-25 08:00AM	Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension (Business Wire)
Mar-07-25 08:40AM	Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock? (Zacks)
Mar-04-25 04:06AM	Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks (StockStory) -5.21%
04:03AM	Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers (StockStory)
Mar-03-25 04:05PM	FDA Files Corcepts New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism (Business Wire)
Feb-28-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT) (Zacks)
09:40AM	Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-27-25 02:31PM	Why Corcept (CORT) Shares Are Sliding Today (StockStory) -5.55%
09:50AM	Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term (Zacks)
09:19AM	Q4 2024 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:26AM	Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-26-25 06:05PM	Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
05:11PM	Corcept: Q4 Earnings Snapshot (Associated Press Finance)
04:43PM	Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings (StockStory)
04:05PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update (Business Wire)
Feb-25-25 08:00AM	Corcept (CORT) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-23-25 03:05PM	Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-18-25 04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-12-25 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Jan-31-25 08:38AM	Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-25 12:00PM	All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy (Zacks)
Jan-24-25 12:45PM	Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:15AM	Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jan-22-25 11:35AM	Medical Stock Soars To Highs As Cortisol Screening Grows (Investor's Business Daily)
Jan-20-25 06:53PM	Heres Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Jan-18-25 01:59PM	Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? (Insider Monkey)
Jan-07-25 08:04AM	Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance (Insider Monkey)
Dec-30-24 05:15PM	Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism (Business Wire)
Dec-24-24 11:13PM	Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? (Insider Monkey)
Dec-17-24 05:16AM	Corcept Therapeutics Cushings syndrome therapy shows promise in Phase III trial (Clinical Trials Arena)
Dec-16-24 08:00AM	Corcepts Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism (Business Wire)
Dec-13-24 08:53AM	Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes (Benzinga)
Dec-12-24 04:05PM	Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushings Syndrome) and Difficult-to-Control Diabetes (Business Wire) -6.25%
Dec-11-24 04:05PM	Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
09:50AM	Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock (Zacks)
Dec-09-24 12:45PM	Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Dec-06-24 09:55AM	Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? (Zacks)
Nov-29-24 11:31AM	Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-25-24 09:50AM	Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-21-24 12:45PM	3 Reasons Growth Investors Will Love Corcept (CORT) (Zacks)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Chief Development Officer	May 06 '25	Option Exercise	21.65	7,060	152,849	12,547	May 08 08:20 PM
Guyer William	Chief Development Officer	May 06 '25	Sale	74.31	7,060	524,653	5,487	May 08 08:20 PM
Maduck Sean	See Remarks	May 02 '25	Option Exercise	5.05	26,554	134,098	112,176	May 05 08:33 PM
Maduck Sean	See Remarks	May 01 '25	Option Exercise	5.05	12,856	64,923	98,478	May 05 08:33 PM
Maduck Sean	See Remarks	May 02 '25	Sale	72.23	26,554	1,917,951	85,622	May 05 08:33 PM
Maduck Sean	See Remarks	May 01 '25	Sale	71.94	12,856	924,818	85,622	May 05 08:33 PM
BELANOFF JOSEPH K	Chief Executive Officer	May 02 '25	Sale	72.90	40,000	2,915,922	2,941,985	May 05 08:28 PM
Lyon Joseph Douglas	See Remarks	May 01 '25	Option Exercise	13.56	9,350	126,786	18,359	May 05 08:26 PM
Lyon Joseph Douglas	See Remarks	May 01 '25	Sale	71.96	9,350	672,781	9,009	May 05 08:26 PM
BELANOFF JOSEPH K	Officer	May 02 '25	Proposed Sale	71.48	350	25,018		May 02 04:01 PM
Maduck Sean	Officer	May 02 '25	Proposed Sale	71.48	20,000	1,429,600		May 02 03:52 PM
Lyon Joseph Douglas	Officer	May 01 '25	Proposed Sale	71.88	5,000	359,400		May 01 04:30 PM
Swisher Daniel N JR	Director	Apr 10 '25	Option Exercise	12.13	2,200	26,686	2,200	Apr 14 05:58 PM
Swisher Daniel N JR	Director	Apr 10 '25	Sale	70.22	2,200	154,484	0	Apr 14 05:58 PM
Swisher Daniel N JR	Director	Apr 10 '25	Proposed Sale	70.22	2,200	154,484		Apr 10 10:07 AM
Maduck Sean	See Remarks	Mar 31 '25	Option Exercise	8.27	100,000	827,000	185,622	Apr 02 08:20 PM
Maduck Sean	See Remarks	Apr 01 '25	Option Exercise	5.05	590	2,980	86,212	Apr 02 08:20 PM
Maduck Sean	See Remarks	Mar 31 '25	Sale	100.54	100,000	10,054,010	85,622	Apr 02 08:20 PM
Maduck Sean	See Remarks	Apr 01 '25	Sale	114.55	590	67,584	85,622	Apr 02 08:20 PM
Lyon Joseph Douglas	See Remarks	Mar 31 '25	Option Exercise	16.55	200,000	3,309,400	209,009	Apr 02 08:15 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '25	Option Exercise	13.56	650	8,814	9,659	Apr 02 08:15 PM
Lyon Joseph Douglas	See Remarks	Mar 31 '25	Sale	100.47	200,000	20,093,511	9,009	Apr 02 08:15 PM
Lyon Joseph Douglas	See Remarks	Apr 01 '25	Sale	114.53	650	74,443	9,009	Apr 02 08:15 PM
Guyer William	Chief Development Officer	Apr 01 '25	Option Exercise	21.65	678	14,679	6,165	Apr 02 08:08 PM
Guyer William	Chief Development Officer	Apr 01 '25	Sale	114.51	678	77,639	5,487	Apr 02 08:08 PM
BELANOFF JOSEPH K	Chief Executive Officer	Mar 31 '25	Sale	94.72	35,102	3,324,861	2,982,335	Apr 02 08:01 PM
BELANOFF JOSEPH K	Chief Executive Officer	Apr 01 '25	Sale	114.71	350	40,148	2,981,985	Apr 02 08:01 PM
BELANOFF JOSEPH K	Officer	Apr 01 '25	Proposed Sale	114.22	40,000	4,568,800		Apr 01 04:09 PM
Guyer William	Officer	Apr 01 '25	Proposed Sale	114.22	20,000	2,284,400		Apr 01 03:23 PM
Lyon Joseph Douglas	Officer	Apr 01 '25	Proposed Sale	114.22	5,000	571,100		Apr 01 03:13 PM
Maduck Sean	Officer	Apr 01 '25	Proposed Sale	114.22	20,000	2,284,400		Apr 01 03:00 PM
Maduck Sean	Officer	Mar 31 '25	Proposed Sale	100.54	100,000	10,054,000		Mar 31 04:29 PM
Lyon Joseph Douglas	Officer	Mar 31 '25	Proposed Sale	100.47	200,000	20,093,500		Mar 31 04:20 PM
Lyon Joseph Douglas	See Remarks	Mar 24 '25	Option Exercise	13.56	421	5,709	9,430	Mar 26 06:55 PM
Lyon Joseph Douglas	See Remarks	Mar 24 '25	Sale	60.58	421	25,504	9,009	Mar 26 06:55 PM
BELANOFF JOSEPH K	Chief Executive Officer	Mar 24 '25	Sale	60.83	1,974	120,084	3,017,437	Mar 26 05:07 PM
Maduck Sean	See Remarks	Mar 24 '25	Option Exercise	5.05	1,697	8,570	87,319	Mar 26 05:07 PM
Maduck Sean	See Remarks	Mar 24 '25	Sale	60.58	1,697	102,804	85,622	Mar 26 05:07 PM
Swisher Daniel N JR	Director	Mar 10 '25	Option Exercise	12.13	2,200	26,686	2,200	Mar 12 04:54 PM
Swisher Daniel N JR	Director	Mar 10 '25	Sale	53.60	2,200	117,920	0	Mar 12 04:54 PM
Swisher Daniel N JR	Director	Mar 10 '25	Proposed Sale	53.60	2,200	117,920		Mar 10 11:02 AM
Maduck Sean	See Remarks	Mar 03 '25	Option Exercise	5.05	18,303	92,430	103,925	Mar 04 08:15 PM
Maduck Sean	See Remarks	Mar 03 '25	Sale	60.69	18,303	1,110,818	85,622	Mar 04 08:15 PM
Lyon Joseph Douglas	See Remarks	Mar 03 '25	Option Exercise	13.56	4,579	62,091	13,588	Mar 04 07:58 PM
Lyon Joseph Douglas	See Remarks	Mar 03 '25	Sale	60.69	4,579	277,902	9,009	Mar 04 07:58 PM
Guyer William	Chief Development Officer	Mar 04 '25	Option Exercise	19.26	20,000	385,200	25,487	Mar 04 07:53 PM
Guyer William	Chief Development Officer	Mar 04 '25	Sale	59.07	20,000	1,181,400	5,487	Mar 04 07:53 PM
BELANOFF JOSEPH K	Chief Executive Officer	Mar 03 '25	Sale	60.91	2,924	178,098	3,019,411	Mar 04 07:44 PM
Guyer William	Officer	Mar 04 '25	Proposed Sale	59.07	20,000	1,181,400		Mar 04 01:59 PM
BELANOFF JOSEPH K	Officer	Mar 03 '25	Proposed Sale	60.58	40,000	2,423,200		Mar 03 01:47 PM
Lyon Joseph Douglas	Officer	Mar 03 '25	Proposed Sale	60.58	5,000	302,900		Mar 03 12:37 PM
Maduck Sean	Officer	Mar 03 '25	Proposed Sale	60.58	20,000	1,211,600		Mar 03 12:18 PM
Hunt Hazel	Chief Scientific Officer	Feb 11 '25	Option Exercise	3.29	150,000	493,500	268,581	Feb 13 08:20 PM
Swisher Daniel N JR	Director	Feb 10 '25	Option Exercise	12.13	2,200	26,686	2,200	Feb 12 08:26 PM
Swisher Daniel N JR	Director	Feb 10 '25	Sale	68.08	2,200	149,776	0	Feb 12 08:26 PM
Swisher Daniel N JR	Director	Feb 10 '25	Proposed Sale	68.08	2,200	149,776		Feb 10 11:36 AM
Maduck Sean	See Remarks	Feb 03 '25	Option Exercise	4.35	20,000	86,976	105,318	Feb 05 04:07 PM
Maduck Sean	See Remarks	Feb 03 '25	Sale	66.92	20,000	1,338,400	85,318	Feb 05 04:07 PM
Lyon Joseph Douglas	See Remarks	Feb 03 '25	Option Exercise	12.87	5,000	64,328	13,759	Feb 05 04:05 PM
Lyon Joseph Douglas	See Remarks	Feb 03 '25	Sale	66.92	5,000	334,600	8,759	Feb 05 04:05 PM
Maduck Sean	Officer	Feb 03 '25	Proposed Sale	66.92	20,000	1,338,400		Feb 03 01:33 PM
Lyon Joseph Douglas	Officer	Feb 03 '25	Proposed Sale	66.92	5,000	334,600		Feb 03 01:17 PM
WILSON JAMES N	Director	Jan 22 '25	Option Exercise	3.29	250,000	822,500	250,000	Jan 24 08:20 PM
Swisher Daniel N JR	Director	Jan 10 '25	Option Exercise	12.13	2,200	26,686	2,200	Jan 14 07:30 PM
Swisher Daniel N JR	Director	Jan 10 '25	Sale	50.54	2,200	111,188	0	Jan 14 07:30 PM
Swisher Daniel N JR	Director	Jan 10 '25	Proposed Sale	50.54	2,200	111,188		Jan 10 10:49 AM
Maduck Sean	See Remarks	Jan 02 '25	Option Exercise	3.88	20,000	77,600	105,318	Jan 06 07:59 PM
Maduck Sean	See Remarks	Jan 02 '25	Sale	50.39	20,000	1,007,800	85,318	Jan 06 07:59 PM
Lyon Joseph Douglas	See Remarks	Jan 02 '25	Option Exercise	11.35	5,000	56,750	13,759	Jan 06 07:24 PM
Lyon Joseph Douglas	See Remarks	Jan 02 '25	Sale	50.39	5,000	251,950	8,759	Jan 06 07:24 PM
Robb Gary Charles	Chief Business Officer	Jan 02 '25	Option Exercise	3.29	11,000	36,190	31,119	Jan 06 07:15 PM
Robb Gary Charles	Chief Business Officer	Jan 03 '25	Option Exercise	3.29	3,037	9,992	23,156	Jan 06 07:15 PM
Robb Gary Charles	Chief Business Officer	Jan 02 '25	Sale	50.50	11,000	555,552	20,119	Jan 06 07:15 PM
Maduck Sean	Officer	Jan 02 '25	Proposed Sale	50.39	20,000	1,007,800		Jan 02 12:03 PM
Robb Gary Charles	Officer	Jan 02 '25	Proposed Sale	50.45	11,000	554,986		Jan 02 11:58 AM
Lyon Joseph Douglas	Officer	Jan 02 '25	Proposed Sale	50.34	5,000	251,693		Jan 02 11:52 AM
Swisher Daniel N JR	Director	Dec 10 '24	Option Exercise	12.13	2,200	26,686	2,200	Dec 12 04:59 PM
Swisher Daniel N JR	Director	Dec 10 '24	Sale	59.46	2,200	130,812	0	Dec 12 04:59 PM
Swisher Daniel N JR	Director	Dec 10 '24	Proposed Sale	59.46	2,200	130,812		Dec 10 10:00 AM
Robb Gary Charles	Chief Business Officer	Nov 22 '24	Sale	56.20	2,609	146,626	20,163	Nov 26 06:16 PM
Lyon Joseph Douglas	See Remarks	Nov 22 '24	Sale	56.72	1,411	80,032	8,494	Nov 26 06:13 PM
Lyon Joseph Douglas	Officer	Nov 22 '24	Proposed Sale	56.72	1,411	80,032		Nov 22 02:36 PM
Robb Gary Charles	Officer	Nov 22 '24	Proposed Sale	56.20	2,609	146,626		Nov 22 11:41 AM
Swisher Daniel N JR	Director	Nov 11 '24	Option Exercise	12.13	2,200	26,686	2,200	Nov 13 08:06 PM
Swisher Daniel N JR	Director	Nov 11 '24	Sale	59.88	2,200	131,736	0	Nov 13 08:06 PM
Swisher Daniel N JR	Director	Nov 11 '24	Proposed Sale	59.88	2,200	131,736		Nov 12 08:21 AM
Guyer William	Chief Development Officer	Nov 01 '24	Option Exercise	21.65	6,606	143,020	12,402	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 04 '24	Option Exercise	21.65	3,394	73,480	9,190	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 01 '24	Sale	48.97	6,606	323,496	5,796	Nov 05 07:48 PM
Guyer William	Chief Development Officer	Nov 04 '24	Sale	48.97	3,394	166,204	5,796	Nov 05 07:48 PM
Guyer William	Officer	Nov 01 '24	Proposed Sale	48.97	10,000	489,700		Nov 01 12:55 PM
Guyer William	Chief Development Officer	Oct 01 '24	Option Exercise	21.65	10,000	216,500	15,796	Oct 03 04:27 PM
Guyer William	Chief Development Officer	Oct 01 '24	Sale	46.28	10,000	462,800	5,796	Oct 03 04:27 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Option Exercise	3.29	11,000	36,190	33,772	Oct 01 07:55 PM
Robb Gary Charles	Chief Business Officer	Oct 01 '24	Sale	46.28	11,000	509,080	22,772	Oct 01 07:55 PM
Robb Gary Charles	Officer	Oct 01 '24	Proposed Sale	46.28	11,000	509,080		Oct 01 12:55 PM
Guyer William	Officer	Oct 01 '24	Proposed Sale	46.28	10,000	462,800		Oct 01 12:44 PM
Guyer William	Chief Development Officer	Sep 03 '24	Option Exercise	21.65	10,000	216,500	16,039	Sep 05 08:04 PM
Guyer William	Chief Development Officer	Sep 03 '24	Sale	35.30	10,000	353,000	6,039	Sep 05 08:04 PM
Guyer William	Officer	Sep 03 '24	Proposed Sale	35.30	10,000	353,000		Sep 03 11:33 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your FINVIZ experience